66 results about "Virus Neutralization" patented technology

The invention relates to the technical field of biological medicines, in particular to a recombinant rabies virus nano-antibody fused with a solubilizing oligopeptide and a cell penetrating peptide and application of the recombinant rabies virus nano-antibody in preparation of rabies prevention and treatment products. The recombinant rabies virus nano-antibody fused with the solubilizing oligopeptide and the cell penetrating peptide comprises a humanized rabies virus nano-antibody, and the C end of the humanized rabies virus nano-antibody is fused with a solubilizing tag peptide P17 and the cell penetrating peptide. The recombinant rabies virus nano antibody utilizes a prokaryotic expression system, is low in cost, has excellent cell membrane and BBB penetrating ability, can enter a central nervous system from veins for virus neutralization treatment, and has an efficient passive immune effect.

The invention belongs to the technical field of biology, and particularly relates to a porcine epidemic diarrhea virus broad-spectrum neutralizing antibody and application thereof. A porcine epidemic diarrhea virus broad-spectrum neutralizing antibody 6G2 is screened, the virus neutralizing activity of the antibody is evaluated through a cell model, and it is found that the antibody can effectively block infection of G1a, G1b, G2a, G2b, G2c and S-INDEL (porcine epidemic diarrhea virus) gene subtype strains with high epidemic rate on cells. Further, animal infection experiments of pigs prove that the neutralizing antibody provided by the invention has good prevention and treatment effects on the porcine epidemic diarrhea virus, and has important significance on improving the capability of preventing and controlling porcine epidemic diarrhea in a pig farm.

The present invention relates to a nanobody against human adenovirus type 4 Hexon protein, which nanobody has a unique CDR region, can bind to adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in a virus neutralization test, and to the use thereof in antiviral therapy. The invention also provides application of the nano antibody in preparation of a medicine for treating and / or preventing human type 4 adenovirus infectious diseases and a diagnostic kit.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

Isolated monoclonal antibodies and antigen binding fragments thereof are disclosed that specifically binds to West Nile Virus. These monoclonal antibodies or antigen binding fragments can inhibit a West Nile Virus infection in a subject, and / or can be used to diagnose a West Nile Virus in a subject. Nucleic acid molecules encoding these antibodies and antigen binding fragments are also disclosed, as are vectors including these nucleic acid molecules, and host cells expressing these vectors.

This invention belongs to the field of biotechnology, specifically relating to a broad-spectrum neutralizing antibody against porcine epidemic diarrhea virus (PEDV) and its applications. This invention screened a broad-spectrum neutralizing antibody against PEDV, 6G2. Cell model evaluation revealed that the antibody effectively blocked infection of cells by several highly prevalent PEDV genotypes: G1a, G1b, G2a, G2b, G2c, and S-INDEL. Further animal infection experiments in pigs demonstrated that the neutralizing antibody provided by this invention has good preventive and therapeutic effects against PEDV, which is of great significance for improving the ability of pig farms to control PEDV.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

The present invention relates to an anti-human adenovirus type 4 Hexon protein nanobody and an application thereof, the nanobody having a unique CDR region, capable of binding to the adenovirus type 4 Hexon protein with high affinity, and capable of neutralizing adenovirus type 4 pseudovirus with high neutralizing activity in a virus neutralization test. The invention also provides application of the nano antibody in preparation of a medicine for treating and / or preventing human type 4 adenovirus infectious diseases and a diagnostic kit.

The application provides a preparation method of a shrimp iridovirus DIV1 neutralizing antibody and application thereof. The gene sequence shown as SEQ ID NO. 1 and the amino acid sequence shown as SEQ ID NO. 2 are used to solve the problem that there is no neutralizing antibody for the shrimp iridovirus DIV1 at present. The antibody for the shrimp iridovirus DIV1 prepared by the application can specifically recognize the DIVI virus and has good virus neutralizing activity, can effectively reduce the death of shrimps caused by DIV1 virus infection, significantly improve the ability of shrimps to resist DIV1 virus infection, and effectively prevent the infection and transmission of the virus.

Provided are an antigen-binding protein neutralizing respiratory syncytial virus (RSV) and a use thereof. The antigen-binding protein comprises a single-domain antibody containing CDR1, CDR2, and CDR3 antigen complementarity-determining regions, and has the function of exerting virus-neutralizing activity by recognizing and binding to RSV surface proteins. The antigen-binding protein can prevent or treat diseases caused by RSV infection.

The invention discloses a cat parvovirus VP2 protein nano antibody as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the cat parvovirus VP2 protein nano antibody is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. According to the invention, an alpaca is immunized by using FPV VP2 protein, a phage display nano antibody library is constructed, and two nano antibodies 3D6 and 1B9 with strong specificity and high affinity are obtained through multiple rounds of panning and identification. Through identification, the nano antibodies 3D6 and 1B9 can be specifically combined with FPV and VP2 proteins, and have high affinity and remarkable virus neutralizing activity. The nano antibody can be used for preparing a detection reagent or kit for feline parvovirus infection, and rapid and accurate diagnosis is realized; the compound can also be used as an active component to prepare a therapeutic drug, and provides a special therapeutic scheme for FPV infection. The nano antibody provides an important material basis for developing a novel diagnostic tool and a specific therapeutic drug aiming at the feline parvovirus.

The present invention relates to a HBV S protein-specific monoclonal antibody, HBV-S-4H7, and its use in the preparation of a detection kit. Based on the amino acid sequences of different HBV S proteins, multiple sequence alignment, and online epitope screening software, the present invention ultimately selects a preferred epitope peptide and immunizes mice to prepare a broad-spectrum monoclonal antibody. The antibody has good binding properties. Based on the role of the S protein in the virus, neutralization experiments confirm that the monoclonal antibody prepared by the present invention also has good virus neutralization effect, and has good application prospects.

The invention discloses an anti-Crimean-Congo hemorrhagic fever virus (CCHFV) neutralizing antibody N013 and application thereof in diagnosis, treatment and / or prevention of Crimean-Congo hemorrhagic fever, and the antibody has a unique CDR region and can be combined with the Gc protein of the CCHFV with high affinity. In a virus neutralization experiment, the antibody N013 disclosed by the invention has strong neutralization activity on CCHFV pseudovirus particles, the IC50 value is 26.63 ng / mL, and the antibody N013 has a wide application prospect in treatment of Crimean-Congo hemorrhagic fever.

The application discloses a humanized anti-SARS-COV-2 virus monoclonal neutralizing antibody, the neutralizing antibody is screened by single B cell flow sorting-antibody gene amplification pairing expression technology, has a unique CDR region, can be specifically combined with SARS-COV-2 and can effectively neutralize SARS-COV-2 wild strains and Omicron BA.5, Omicron XBB.1.5, Omicron EG.5, Omicron JN.1, Omicron KP.2 and other Omicron mutant strains, the IC50 is lower than 0.1 μg / mL, has broad-spectrum virus neutralization activity, and the application also relates to application of the antibody in preparation of a new coronavirus disease treatment or prevention drug and a detection reagent, the antibody has the characteristics of full humanization, high expression and good stability, and is suitable for industrialization.

The invention discloses a double-epitope alpaca source nano antibody and application thereof, and belongs to the field of biological medicine. Aiming at different epitopes of MERS-CoV, specific screening is carried out by immunizing alpaca and utilizing a ribosome display nano antibody library, and VHH epitopes and molecular docking are identified by utilizing a pseudovirus neutralization experiment, a competitive BLI experiment and a phage random peptide library, so that two antibodies 2-77 and 4-58 aiming at different binding sites of MERS-CoV RBD are obtained. And the double-epitope alpaca source nano antibody 2F4 which is good in neutralizing activity, high in expression quantity and stable is constructed from the two strains of nano antibodies. A focus formation test and a mouse in-vivo experiment prove that the constructed double-epitope alpaca source nano antibody 2F4 can effectively neutralize the MERS-CoV and effectively protect animals, and a thought and a technical support are provided for exploring brand-new antigen epitopes and designing therapeutic antibody drugs for the MERS-CoV.

The invention discloses a chikungunya virus monoclonal antibody and application thereof in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The application belongs to the field of molecular biology and particularly relates to an anti-CD4 nanobody with a longer plasma half-life, which comprises a CD4 targeting domain and an HSA targeting domain; the CD4 targeting domain comprises three complementarity determining regions CDR1-3, and the sequences are shown in SEQ ID NO:1-3 in sequence; the HSA targeting domain comprises three complementarity determining regions CDR1-3, and the sequences are shown in SEQ ID NO:4-6 in sequence. The application develops a nanobody drug for attacking the target point CD4 of HIV, and constructs a "Ushanka" type nanobody NbCD4-NbHSA-NbCD4 by introducing an anti-HSA VHH, so that the half-life of the nanobody can be effectively improved; meanwhile, the efficacy of the single nanobody and the "Ushanka" type nanobody in treating HIV infection is evaluated by using a pseudovirus neutralization experiment. The application provides a potential effective nanobody new drug for the clinical treatment of HIV.

The present application relates to a kind of polypeptide NbM14 identifiable and neutralizing MERS-CoV, including 3 complementarity determining regions CDR1-3, sequence as SEQ ID NO:1-3 show.The present application carries out nanobody drug development to MERS-CoV, by preparing MERS-CoV S protein, immunizing bactrian camel, utilizes phage library display nanomantibody platform technology etc., screen to the nanobody VHH specific binding MERS-CoV, identify its CDR sequence, and construct humanized VHH-huFc1;Simultaneously, using pseudovirus neutralization experiment evaluates the curative effect of NbM14 in the treatment of MERS-CoV infection, provides potential detection agent and therapeutic drug for the prevention and treatment of MERS-CoV infection.

The present application relates to a kind of anti-procambarus clarkii white spot syndrome virus monoclonal antibody and its application, the complementary determining region CDR1-3 sequence of the heavy chain variable region of the anti-procambarus clarkii white spot syndrome virus monoclonal antibody is sequentially shown as SEQ ID NO:3-5, the complementary determining region CDR1-3 sequence of the light chain variable region is sequentially shown as SEQ ID NO:6-8.The present application successfully obtains the high affinity of anti-VP28 monoclonal antibody, and it has excellent affinity to procambarus clarkii white spot syndrome virus.The monoclonal antibody can be used for specific detection to procambarus clarkii white spot syndrome virus, and has good virus neutralization activity.By adding the monoclonal antibody in water body, the resistance of procambarus clarkii to white spot syndrome virus can be greatly improved, easy to operate, without injection, suitable for large-scale breeding scene, provide a new technical means for the prevention and control of white spot syndrome virus disease in aquaculture.

The invention provides an anti-orthopoxvirus monoclonal antibody and application thereof, the monoclonal antibody is obtained by screening through a flow cytometry sorting technology and a single cell PCR technology, has a unique CDR partition, and is mainly used for recognizing L1R (M1R) antigen protein of orthopoxvirus. The affinity of the antibody to VARV (Vector Activated Receptor Virus), VACV (Vector Activated Receptor Virus), CPXV (Cytopoxvirus) and MPXV (Metapoxvirus) of orthopoxvirus is 1.84 nM, 1.46 nM, 2.71 nM and 2.57 nM respectively. In a virus neutralization experiment, the IC50 of the antibody and mature virions in vaccinia virus cells is 37.93 pM. In a monkey pox virus infected mouse model, the antibody can treat a monkey pox virus infected mouse. The monoclonal antibody disclosed by the invention has the characteristics of high expression, high neutralizing activity and good broad spectrum, can be used for industrial production, and can be applied to coping with orthopoxvirus infection outbreak possibly occurring in the future.

The application discloses a monoclonal antibody specifically binding to coxsackievirus A6 and application thereof. The monoclonal antibody comprises a light chain and a heavy chain, the amino acid sequence of the complementarity determining region HCDR1 of the heavy chain is shown as SEQ ID No:1, the amino acid sequence of the complementarity determining region HCDR2 of the heavy chain is shown as SEQ ID No:4, the amino acid sequence of the complementarity determining region HCDR3 of the heavy chain is shown as SEQ ID No:7, the amino acid sequence of the complementarity determining region LCDR1 of the light chain is shown as SEQ ID No:10, the amino acid sequence of the complementarity determining region LCDR2 of the light chain is shown as GTS, and the amino acid sequence of the complementarity determining region LCDR3 of the light chain is shown as SEQ ID No:13. The monoclonal antibody has good specificity and sensitivity and has a virus neutralization capacity, and shows great potential in virus identification, diagnosis, treatment and development of multivalent vaccines.

The application provides two kinds of anti-rabies virus full human monoclonal antibodies or a combination thereof, a heavy chain variable region of the antibodies comprises three CDR regions, sequences of the three CDR regions are respectively shown as SEQ ID NO:1-3 and SEQ ID NO:9-11, and a light chain variable region of the antibodies comprises three CDR regions, sequences of the three CDR regions are respectively shown as SEQ ID NO:4-6 and SEQ ID NO:12-14. The application also provides application of the antibodies to anti-rabies virus. The antibodies are high in affinity to different antigen epitopes of a rabies virus G protein, and are high in potency in neutralizing rabies virus strains derived from different genetic subtypes, and the combination of the antibodies does not affect antigen binding and virus neutralization activities of the antibodies.

The present invention relates to a nanobody directed against the human adenovirus type 4 Hexon protein and its use in antiviral therapy. The nanobody has a unique CDR region, can bind to the adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in virus neutralization assays. The present invention also provides the use of the nanobody in the preparation of a drug for treating and / or preventing diseases caused by human adenovirus type 4, as well as a diagnostic kit.

This invention provides a neutralizing monoclonal antibody B36B9 against orthopoxvirus and its applications. The monoclonal antibody, obtained through flow cytometry sorting and single-cell PCR, possesses a unique CDR region and primarily recognizes the L1R (M1R) antigen protein of orthopoxvirus. The antibody exhibits affinities of 0.21 nM, 0.39 nM, 0.03 nM, and 0.12 nM for VARV, VACV, CPXV, and MPXV, respectively. In virus neutralization experiments, the antibody showed an IC50 value of [missing information - likely related to viral neutralization]. 50 The titer was 41.13 nM. In a mouse model of monkeypox virus infection, the antibody significantly reduced the viral titer in the lungs of mice. The monoclonal antibody provided by this invention has the characteristics of high expression, high affinity, and broad spectrum, and has the potential for application in the preparation of therapeutic and preventive drugs for monkeypox virus or kits for detecting monkeypox virus.

The present invention relates to a polypeptide NbM9 that can recognize and neutralize MERS-CoV, comprising three complementary determining regions (CDR1-3), the sequences of which are shown in SEQ ID NOs: 1-3. The present invention develops nanoantibody drugs targeting MERS-CoV. By preparing the MERS-CoV S protein, immunizing Bactrian camels, and utilizing a phage library platform technology to display nanomonoclonal antibodies, a nanoantibody VHH that specifically binds to MERS-CoV was screened, its CDR sequence was identified, and a humanized VHH-huFc1 was constructed. Simultaneously, a pseudovirus neutralization experiment was used to evaluate the efficacy of NbM9 in treating MERS-CoV infection, providing a potential detection agent and therapeutic drug for the prevention and treatment of MERS-CoV infection.

The present application relates to a kind of anti-procambarus clarkii white spot syndrome virus monoclonal antibody and its application, the complementary determining region CDR1-3 sequence of the heavy chain variable region of the anti-procambarus clarkii white spot syndrome virus monoclonal antibody is sequentially shown as SEQ ID NO:3-5, the complementary determining region CDR1-3 sequence of the light chain variable region is sequentially shown as SEQ ID NO:6-8.The present application successfully obtains the high affinity of anti-VP28 monoclonal antibody, and it has excellent affinity to procambarus clarkii white spot syndrome virus.The monoclonal antibody can be used for specific detection to procambarus clarkii white spot syndrome virus, and has good virus neutralization activity.By adding the monoclonal antibody in water body, the resistance of procambarus clarkii to white spot syndrome virus can be greatly improved, easy to operate, without injection, suitable for large-scale breeding scene, provide a new technical means for the prevention and control of white spot syndrome virus disease in aquaculture.

The invention relates to a multivalent vaccine, in particular to a chimera multivalent vaccine based on Ercovirus type 11, 18 and 30 key epitopes as well as a preparation method and application of the chimera multivalent vaccine. According to the invention, a chimera multivalent vaccine VP1-III is also designed based on key epitopes, an E11-VP1 sequence is taken as a basis, one E18-VP1 key epitope and two E30-VP1 key epitopes are respectively inserted into the E11-VP1 sequence to obtain a chimera multivalent protein vaccine VP1-III, and the chimera multivalent protein vaccine VP1-III is taken as an immunogen to immunize a mouse to detect antibody titer and virus neutralizing capacity of antiserum. A new thought is provided for designing and preparing multivalent vaccines and detecting immunogenicity of viral vaccines.